Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00453999 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00453999 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 137 participants.
The verdict
NCT00453999, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
This study has been designed as a randomized, double-blind, controlled, study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg) versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute serious or potentially life threatening influenza. Study treatments will be provided for up to 5 consecutive days.
Interventions
- DRUG Oseltamivir
- DRUG Peramivir 200 mg
- DRUG Peramivir 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00453999
The ClinicalTrials.gov registry entry for NCT00453999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oseltamivir is the first listed.
NCT00453999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00453999 about?
NCT00453999 is a clinical study titled "Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza". This study has been designed as a randomized, double-blind, controlled, study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg) versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute serious or potentially life...
What is the current status of trial NCT00453999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2007-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00453999?
The interventions under investigation include: Oseltamivir (DRUG), Peramivir 200 mg (DRUG), Peramivir 400 mg (DRUG).
Who is sponsoring clinical trial NCT00453999?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.